Pharmacokinetics and pharmacodynamics of 3 dosages of oestriol after continuous vaginal ring administration for 21 days in healthy, postmenopausal women
ConclusionAll formulations released sufficient amounts of oestriol to trigger the maximum local effect. However, there was no difference between formulations regarding surrogate parameters for clinical efficacy. A dose ‐dependency; however, was clearly demonstrated for FSH and LH. The product was well tolerated and safe. (Source: British Journal of Clinical Pharmacology)
Source: British Journal of Clinical Pharmacology - November 27, 2018 Category: Drugs & Pharmacology Authors: R.V. Oliveira Filho, N.J. Antunes, J.O. Ilha, R.A. Moreno, R. Wedemeyer, A. Warnke, G. De Nucci Tags: ORIGINAL ARTICLE Source Type: research

Nightmares and hallucinations with aprepitant and opium powder: a suspected drug –drug interaction
We describe a strongly suspected elderly cancer patient's DDI between aprepitant and opium powder in the context of an irinotecan‐based regimen manifested by nightmares and visual hallucinations. We discuss this DDI's hypothetical pharmacological mech anisms and management. (Source: British Journal of Clinical Pharmacology)
Source: British Journal of Clinical Pharmacology - November 26, 2018 Category: Drugs & Pharmacology Authors: Gr égoire Narjoux, Justine Clarenne, Brahim Azzouz, Pauline‐Saraï Zeller, Florian Slimano, Olivier Bouché Tags: CASE REPORT Source Type: research

Identifying poor adherence to antihypertensive medications in patients with resistant hypertension
British Journal of Clinical Pharmacology, EarlyView. (Source: British Journal of Clinical Pharmacology)
Source: British Journal of Clinical Pharmacology - November 26, 2018 Category: Drugs & Pharmacology Authors: Isla S. Mackenzie, Thomas M. MacDonald Tags: EDITORIAL Source Type: research

Issue Information
No abstract is available for this article. (Source: British Journal of Clinical Pharmacology)
Source: British Journal of Clinical Pharmacology - November 26, 2018 Category: Drugs & Pharmacology Tags: ISSUE INFORMATION Source Type: research

Issue highlights
British Journal of Clinical Pharmacology, Volume 84, Issue 12, Page 2685-2686, December 2018. (Source: British Journal of Clinical Pharmacology)
Source: British Journal of Clinical Pharmacology - November 26, 2018 Category: Drugs & Pharmacology Tags: ISSUE HIGHLIGHTS Source Type: research

Nightmares and hallucinations with aprepitant and opium powder: a suspected drug –drug interaction
We describe a strongly suspected elderly cancer patient's DDI between aprepitant and opium powder in the context of an irinotecan‐based regimen manifested by nightmares and visual hallucinations. We discuss this DDI's hypothetical pharmacological mech anisms and management. (Source: British Journal of Clinical Pharmacology)
Source: British Journal of Clinical Pharmacology - November 26, 2018 Category: Drugs & Pharmacology Authors: Gr égoire Narjoux, Justine Clarenne, Brahim Azzouz, Pauline‐Saraï Zeller, Florian Slimano, Olivier Bouché Tags: CASE REPORT Source Type: research

Identifying poor adherence to antihypertensive medications in patients with resistant hypertension
British Journal of Clinical Pharmacology, EarlyView. (Source: British Journal of Clinical Pharmacology)
Source: British Journal of Clinical Pharmacology - November 26, 2018 Category: Drugs & Pharmacology Authors: Isla S. Mackenzie, Thomas M. MacDonald Tags: EDITORIAL Source Type: research

Issue Information
No abstract is available for this article. (Source: British Journal of Clinical Pharmacology)
Source: British Journal of Clinical Pharmacology - November 26, 2018 Category: Drugs & Pharmacology Tags: ISSUE INFORMATION Source Type: research

Issue highlights
British Journal of Clinical Pharmacology, Volume 84, Issue 12, Page 2685-2686, December 2018. (Source: British Journal of Clinical Pharmacology)
Source: British Journal of Clinical Pharmacology - November 26, 2018 Category: Drugs & Pharmacology Tags: ISSUE HIGHLIGHTS Source Type: research

The Developing Regorafenib Eye drops for neovascular Age ‐related Macular degeneration (DREAM) study: an open‐label phase II trial
ConclusionsThe programme was terminated after phase IIa ended because efficacy was lower than with current nAMD treatments. According to elaboratepost hoc analyses, the most likely reason was insufficient exposure in the target compartment (back of the eye). (Source: British Journal of Clinical Pharmacology)
Source: British Journal of Clinical Pharmacology - November 25, 2018 Category: Drugs & Pharmacology Authors: Antonia M. Joussen, Sebastian Wolf, Peter K. Kaiser, David Boyer, Thomas Schmelter, Rupert Sandbrink, Oliver Zeitz, Gesa Deeg, Annett Richter, Torsten Zimmermann, Joachim Hoechel, Ulf Buetehorn, Walter Schmitt, Brigitte Stemper, Michael K. B Tags: ORIGINAL ARTICLE Source Type: research

Clinical and Translational Pharmacological Aspects of the Management of Fibrous Dysplasia of Bone
AbstractFibrous dysplasia (FD) is a genetic, non ‐inheritable rare bone disease caused by a post‐zygotic activating mutation of the alpha subunit of the stimulatory G‐protein (Gαs) causing increased abnormal bone formation leading to pain, deformity and fractures. To date, no cure has been identified for FD/MAS and treatment is symptomatic and aimed at decreasing pain and/or local bone turnover. Various drugs have been used to achieve clinical improvement in FD/MAS patients including bisphosphonates and denosumab, however further translational studies are also warranted to address unresolved pathophysiological ...
Source: British Journal of Clinical Pharmacology - November 24, 2018 Category: Drugs & Pharmacology Authors: M. Rotman, N.A.T. Hamdy, N.M. Appelman ‐Dijkstra Tags: REVIEW ‐THEMED ISSUE Source Type: research

Pharmacogenetics of artemether ‐lumefantrine influence on nevirapine disposition: clinically significant drug‐drug interaction?
ConclusionsThis approach highlights additional increase in the already existing risk of suboptimal trough plasma concentration, especially in extensive metabolisers when nevirapine is co ‐administered with artemether‐lumefantrine. (Source: British Journal of Clinical Pharmacology)
Source: British Journal of Clinical Pharmacology - November 24, 2018 Category: Drugs & Pharmacology Authors: Sa ’ad T. Abdullahi, Adeniyi Olagunju, Julius O. Soyinka, Rahman A. Bolarinwa, Olusola J. Olarewaju, Moji T. Bakare‐Odunola, Andrew Owen, Saye Khoo Tags: ORIGINAL ARTICLE Source Type: research

Clinical and Translational Pharmacological Aspects of the Management of Fibrous Dysplasia of Bone
AbstractFibrous dysplasia (FD) is a genetic, non ‐inheritable rare bone disease caused by a post‐zygotic activating mutation of the alpha subunit of the stimulatory G‐protein (Gαs) causing increased abnormal bone formation leading to pain, deformity and fractures. To date, no cure has been identified for FD/MAS and treatment is symptomatic and aimed at decreasing pain and/or local bone turnover. Various drugs have been used to achieve clinical improvement in FD/MAS patients including bisphosphonates and denosumab, however further translational studies are also warranted to address unresolved pathophysiological ...
Source: British Journal of Clinical Pharmacology - November 24, 2018 Category: Drugs & Pharmacology Authors: M. Rotman, N.A.T. Hamdy, N.M. Appelman ‐Dijkstra Tags: REVIEW ‐THEMED ISSUE Source Type: research

Pharmacogenetics of artemether ‐lumefantrine influence on nevirapine disposition: clinically significant drug‐drug interaction?
ConclusionsThis approach highlights additional increase in the already existing risk of suboptimal trough plasma concentration, especially in extensive metabolisers when nevirapine is co ‐administered with artemether‐lumefantrine. (Source: British Journal of Clinical Pharmacology)
Source: British Journal of Clinical Pharmacology - November 24, 2018 Category: Drugs & Pharmacology Authors: Sa ’ad T. Abdullahi, Adeniyi Olagunju, Julius O. Soyinka, Rahman A. Bolarinwa, Olusola J. Olarewaju, Moji T. Bakare‐Odunola, Andrew Owen, Saye Khoo Tags: ORIGINAL ARTICLE Source Type: research

Update on pharmacologically ‐relevant vitamin D analogues
Pharmacologists have been interested in vitamin D since its metabolism was elucidated in the early 1970s. Despite the synthesis of thousands of vitamin D analogues in the hope of separating its calcemic and anti ‐proliferative properties, few molecules have reached the market for use in the treatment of clinical conditions from psoriasis to chronic kidney disease. This review discusses vitamin D drugs, recently developed or still under development, for use in various diseases, but in particular bone disea se. In the process we explore the mechanisms postulated to explain the action of these vitamin D analogues including ...
Source: British Journal of Clinical Pharmacology - November 22, 2018 Category: Drugs & Pharmacology Authors: Glenville Jones, Martin Kaufmann Tags: REVIEW ‐THEMED ISSUE Source Type: research

Integrating anatomo ‐physiological changes and pharmacogenomics in anti‐infective therapy management: is it a major concern?
Success of anti ‐infective therapy is a major challenge in some patients given anatomo‐physiological changes and genetic variations. In this case anecdote, we report the management strategy of a patient suffering from chronic pulmonary aspergillosis in a context of anorexia nervosa and genetic polymorphism. (Source: British Journal of Clinical Pharmacology)
Source: British Journal of Clinical Pharmacology - November 16, 2018 Category: Drugs & Pharmacology Authors: Laura Beaumier, S ébastien Chanoine, Elodie Gautier‐Veyret, Hélène Pluchart, Muriel Cornet, Marie‐Pierre Brenier‐Pinchart, Xavier Fonrose, Boubou Camara, Pierrick Bedouch Tags: CASE REPORT Source Type: research

Plasma extracellular nanovesicle (exosome) ‐derived biomarkers for drug metabolism pathways: a novel approach to characterize variability in drug exposure
ConclusionsConsistent strong concordance was observed between exosome ‐derived CYP3A4 biomarkers and midazolam CL/F. The significance of these results is that CYP3A4 is the drug‐metabolizing enzyme of greatest clinical importance and variability in CYP3A4 activity is poorly described by existing precision dosing strategies. (Source: British Journal of Clinical Pharmacology)
Source: British Journal of Clinical Pharmacology - November 16, 2018 Category: Drugs & Pharmacology Authors: Andrew Rowland, Warit Ruanglertboon, Madel é Dyk, Dhilushi Wijayakumara, Linda S. Wood, Robyn Meech, Peter I. Mackenzie, A. David Rodrigues, Jean‐Claude Marshall, Michael J. Sorich Tags: ORIGINAL ARTICLE Source Type: research

Integrating anatomo ‐physiological changes and pharmacogenomics in anti‐infective therapy management: is it a major concern?
Success of anti ‐infective therapy is a major challenge in some patients given anatomo‐physiological changes and genetic variations. In this case anecdote, we report the management strategy of a patient suffering from chronic pulmonary aspergillosis in a context of anorexia nervosa and genetic polymorphism. (Source: British Journal of Clinical Pharmacology)
Source: British Journal of Clinical Pharmacology - November 16, 2018 Category: Drugs & Pharmacology Authors: Laura Beaumier, S ébastien Chanoine, Elodie Gautier‐Veyret, Hélène Pluchart, Muriel Cornet, Marie‐Pierre Brenier‐Pinchart, Xavier Fonrose, Boubou Camara, Pierrick Bedouch Tags: CASE REPORT Source Type: research

Plasma extracellular nanovesicle (exosome) ‐derived biomarkers for drug metabolism pathways: a novel approach to characterize variability in drug exposure
ConclusionsConsistent strong concordance was observed between exosome ‐derived CYP3A4 biomarkers and midazolam CL/F. The significance of these results is that CYP3A4 is the drug‐metabolizing enzyme of greatest clinical importance and variability in CYP3A4 activity is poorly described by existing precision dosing strategies. (Source: British Journal of Clinical Pharmacology)
Source: British Journal of Clinical Pharmacology - November 16, 2018 Category: Drugs & Pharmacology Authors: Andrew Rowland, Warit Ruanglertboon, Madel é Dyk, Dhilushi Wijayakumara, Linda S. Wood, Robyn Meech, Peter I. Mackenzie, A. David Rodrigues, Jean‐Claude Marshall, Michael J. Sorich Tags: ORIGINAL ARTICLE Source Type: research

Physiologically ‐based pharmacokinetic modelling to predict oprozomib CYP3A drug‐drug interaction potential in patients with advanced malignancies
ConclusionsThese results indicate oprozomib has a low potential to inhibit the metabolism of CYP3A4 substrates in humans. The study shows that cultured human hepatocytes are a more reliable system for DDI prediction than human liver microsomes for studying this class of compounds. Developing a PBPK model prior to a clinical DDI study has been valuable in supporting clinical development of oprozomib. (Source: British Journal of Clinical Pharmacology)
Source: British Journal of Clinical Pharmacology - November 14, 2018 Category: Drugs & Pharmacology Authors: Ying Ou, Yang Xu, Lia Gore, R. Donald Harvey, Alain Mita, Kyriakos P. Papadopoulos, Zhengping Wang, Richard E. Cutler, Dawn E. Pinchasik, Apostolia M. Tsimberidou Tags: ORIGINAL ARTICLE Source Type: research

Effectiveness and safety of 110 or 150 mg dabigatran versus vitamin K antagonists in non ‐valvular atrial fibrillation.
ConclusionIn real life D110 and D150 were at least as effective and safer than VKA. (Source: British Journal of Clinical Pharmacology)
Source: British Journal of Clinical Pharmacology - November 13, 2018 Category: Drugs & Pharmacology Authors: Patrick Blin, Caroline Dureau ‐Pournin, Yves Cottin, Jacques Bénichou, Patrick Mismetti, Abdelilah Abouelfath, Regis Lassalle, Cécile Droz, Nicholas Moore Tags: ORIGINAL ARTICLE Source Type: research

Comparative safety and effectiveness of direct oral anticoagulants in patients with atrial fibrillation in clinical practice in Scotland
ConclusionsAll DOACs were similarly effective in preventing strokes and systemic embolisms, while patients being treated with rivaroxaban exhibited the highest bleeding risks. Observed differences in the risks of all ‐cause mortality, myocardial infarction, and pulmonary embolism warrant further research. (Source: British Journal of Clinical Pharmacology)
Source: British Journal of Clinical Pharmacology - November 13, 2018 Category: Drugs & Pharmacology Authors: Tanja Mueller, Samantha Alvarez ‐Madrazo, Chris Robertson, Olivia Wu, Marion Bennie Tags: ORIGINAL ARTICLE Source Type: research

Effectiveness and safety of 110 or 150 mg dabigatran versus vitamin K antagonists in non ‐valvular atrial fibrillation.
ConclusionIn real life D110 and D150 were at least as effective and safer than VKA. (Source: British Journal of Clinical Pharmacology)
Source: British Journal of Clinical Pharmacology - November 13, 2018 Category: Drugs & Pharmacology Authors: Patrick Blin, Caroline Dureau ‐Pournin, Yves Cottin, Jacques Bénichou, Patrick Mismetti, Abdelilah Abouelfath, Regis Lassalle, Cécile Droz, Nicholas Moore Tags: ORIGINAL ARTICLE Source Type: research

Comparative safety and effectiveness of direct oral anticoagulants in patients with atrial fibrillation in clinical practice in Scotland
ConclusionsAll DOACs were similarly effective in preventing strokes and systemic embolisms, while patients being treated with rivaroxaban exhibited the highest bleeding risks. Observed differences in the risks of all ‐cause mortality, myocardial infarction, and pulmonary embolism warrant further research. (Source: British Journal of Clinical Pharmacology)
Source: British Journal of Clinical Pharmacology - November 13, 2018 Category: Drugs & Pharmacology Authors: Tanja Mueller, Samantha Alvarez ‐Madrazo, Chris Robertson, Olivia Wu, Marion Bennie Tags: ORIGINAL ARTICLE Source Type: research

Reply to ‘Overuse or underuse of methylphenidate in adults in France: commentary on Pauly et al. 2018’ by Weibel et al.
British Journal of Clinical Pharmacology, EarlyView. (Source: British Journal of Clinical Pharmacology)
Source: British Journal of Clinical Pharmacology - November 12, 2018 Category: Drugs & Pharmacology Authors: Vanessa Pauly, Elisabeth Frauger, Marion Lepelley, Michel Mallaret, Quentin Boucherie, Joelle Micallef Tags: LETTER TO THE EDITOR Source Type: research

Prolonged central apnoea after intravenous morphine administration in a 12 ‐year‐old male with a UGT1A1 loss‐of‐function polymorphism
Adverse eventRepeated and prolonged episodes of central apnoea and hypoxia after receiving intravenous morphine for analgesia and ketamine for sedation.Drug implicatedIntravenous morphine sulfate.The patientPreviously healthy 12 ‐year‐old male with no history of sleep apnoea who presented with distal tibia and fibula fracture.Evidence that links drug to eventPharmacogenomic testing revealed that the patient was homozygous for the T allele at the rs887829 SNP inUGT1A1, an enzyme involved in the metabolism of morphine. This polymorphism is a loss ‐of‐function variant, leading to impaired metabolism of morphine.Mechan...
Source: British Journal of Clinical Pharmacology - November 12, 2018 Category: Drugs & Pharmacology Authors: Michael S. Toce, Hyun Kim, Sarita Chung, Baruch S. Krauss Tags: CASE REPORT Source Type: research

Self ‐poisoning with 60 tablets of Apixaban, a pharmacokinetics case report
This report suggests that the use of activated charcoal should be effective up to 17  h after a massive intake. (Source: British Journal of Clinical Pharmacology)
Source: British Journal of Clinical Pharmacology - November 12, 2018 Category: Drugs & Pharmacology Authors: B énédicte Franck, Sylvain Dulaurent, Souleiman El Balkhi, Caroline Monchaud, Nicolas Picard, Sylvain Couderc, Pierre Marquet, Franck Saint‐Marcoux, Jean‐Baptiste Woillard Tags: CASE REPORT Source Type: research

Once ‐daily darunavir/ritonavir 400/100 mg in triple therapy: efficacy and penetration in seminal compartment in ANRS‐165 DARULIGHT study
British Journal of Clinical Pharmacology, EarlyView. (Source: British Journal of Clinical Pharmacology)
Source: British Journal of Clinical Pharmacology - November 12, 2018 Category: Drugs & Pharmacology Authors: Minh P. L ê, Marie‐Laure Chaix, François Raffi, Sylvie Chevret, Sébastien Gallien, Christine Katlama, Pierre Delobel, Yazdan Yazdanpanah, Juliette Saillard, Jean‐Michel Molina, Gilles Peytavin, the ANRS‐165 DARULIGHT study group Tags: LETTER TO THE EDITOR Source Type: research

Restricting maintenance allopurinol dose according to kidney function in patients with gout is inappropriate!
British Journal of Clinical Pharmacology, EarlyView. (Source: British Journal of Clinical Pharmacology)
Source: British Journal of Clinical Pharmacology - November 12, 2018 Category: Drugs & Pharmacology Authors: Lisa K. Stamp, Daniel F.B. Wright, Nicola Dalbeth Tags: LETTER TO THE EDITOR Source Type: research

Teicoplanin hypersensitivity during anaesthesia and surgery
British Journal of Clinical Pharmacology, EarlyView. (Source: British Journal of Clinical Pharmacology)
Source: British Journal of Clinical Pharmacology - November 12, 2018 Category: Drugs & Pharmacology Authors: Paul James Antony Sice, Sarah Ford, Andrew Francis Whyte, James Robertson Greig Tags: LETTER TO THE EDITOR Source Type: research

Reply to ‘Overuse or underuse of methylphenidate in adults in France: commentary on Pauly et al. 2018’ by Weibel et al.
British Journal of Clinical Pharmacology, EarlyView. (Source: British Journal of Clinical Pharmacology)
Source: British Journal of Clinical Pharmacology - November 12, 2018 Category: Drugs & Pharmacology Authors: Vanessa Pauly, Elisabeth Frauger, Marion Lepelley, Michel Mallaret, Quentin Boucherie, Joelle Micallef Tags: LETTER TO THE EDITOR Source Type: research

Prolonged central apnoea after intravenous morphine administration in a 12 ‐year‐old male with a UGT1A1 loss‐of‐function polymorphism
Adverse eventRepeated and prolonged episodes of central apnoea and hypoxia after receiving intravenous morphine for analgesia and ketamine for sedation.Drug implicatedIntravenous morphine sulfate.The patientPreviously healthy 12 ‐year‐old male with no history of sleep apnoea who presented with distal tibia and fibula fracture.Evidence that links drug to eventPharmacogenomic testing revealed that the patient was homozygous for the T allele at the rs887829 SNP inUGT1A1, an enzyme involved in the metabolism of morphine. This polymorphism is a loss ‐of‐function variant, leading to impaired metabolism of morphine.Mechan...
Source: British Journal of Clinical Pharmacology - November 12, 2018 Category: Drugs & Pharmacology Authors: Michael S. Toce, Hyun Kim, Sarita Chung, Baruch S. Krauss Tags: CASE REPORT Source Type: research

Self ‐poisoning with 60 tablets of Apixaban, a pharmacokinetics case report
This report suggests that the use of activated charcoal should be effective up to 17  h after a massive intake. (Source: British Journal of Clinical Pharmacology)
Source: British Journal of Clinical Pharmacology - November 12, 2018 Category: Drugs & Pharmacology Authors: B énédicte Franck, Sylvain Dulaurent, Souleiman El Balkhi, Caroline Monchaud, Nicolas Picard, Sylvain Couderc, Pierre Marquet, Franck Saint‐Marcoux, Jean‐Baptiste Woillard Tags: CASE REPORT Source Type: research

Once ‐daily darunavir/ritonavir 400/100 mg in triple therapy: efficacy and penetration in seminal compartment in ANRS‐165 DARULIGHT study
British Journal of Clinical Pharmacology, EarlyView. (Source: British Journal of Clinical Pharmacology)
Source: British Journal of Clinical Pharmacology - November 12, 2018 Category: Drugs & Pharmacology Authors: Minh P. L ê, Marie‐Laure Chaix, François Raffi, Sylvie Chevret, Sébastien Gallien, Christine Katlama, Pierre Delobel, Yazdan Yazdanpanah, Juliette Saillard, Jean‐Michel Molina, Gilles Peytavin, the ANRS‐165 DARULIGHT study group Tags: LETTER TO THE EDITOR Source Type: research

Restricting maintenance allopurinol dose according to kidney function in patients with gout is inappropriate!
British Journal of Clinical Pharmacology, EarlyView. (Source: British Journal of Clinical Pharmacology)
Source: British Journal of Clinical Pharmacology - November 12, 2018 Category: Drugs & Pharmacology Authors: Lisa K. Stamp, Daniel F.B. Wright, Nicola Dalbeth Tags: LETTER TO THE EDITOR Source Type: research

Teicoplanin hypersensitivity during anaesthesia and surgery
British Journal of Clinical Pharmacology, EarlyView. (Source: British Journal of Clinical Pharmacology)
Source: British Journal of Clinical Pharmacology - November 12, 2018 Category: Drugs & Pharmacology Authors: Paul James Antony Sice, Sarah Ford, Andrew Francis Whyte, James Robertson Greig Tags: LETTER TO THE EDITOR Source Type: research

Pharmacokinetic ‐pharmacodynamic modelling of platelet response to ticagrelor in stable coronary artery disease and prior myocardial infarction patients
ConclusionsIn patients with stable CAD or a history of MI, near maximal platelet inhibition is achieved with both ticagrelor 60 and 90 mg twice daily. At modeled doses below 60mg, the response is overall reduced, more variable between patients, and patients will display greater peak ‐to‐trough variability. (Source: British Journal of Clinical Pharmacology)
Source: British Journal of Clinical Pharmacology - November 10, 2018 Category: Drugs & Pharmacology Authors: Magnus Åstrand, Carl Amilon, Daniel Röshammar, Anders Himmelmann, Dominick J. Angiolillo, Robert F. Storey, Paul A. Gurbel, Marc P. Bonaca, Bengt Hamrén Tags: ORIGINAL ARTICLE Source Type: research

The Impact of Tacrolimus Exposure on Extrarenal Adverse Effects in Adult Renal Transplant Recipients
ConclusionsSeveral AEs (i.e., diarrhea, dyspepsia, insomnia, and neurologic AE ratio) were associated with tacrolimus dose normalized AUCss,0 ‐12hr, and clearance. Skin changes and acne were associated with dose ‐normalized CMAX concentrations. To facilitate clinical implementation, a LSS was developed to predict AUCss,0 ‐12hr values using sparse patient data to efficiently assess projected immunosuppressive exposure and potentially minimize AE manifestations. (Source: British Journal of Clinical Pharmacology)
Source: British Journal of Clinical Pharmacology - November 10, 2018 Category: Drugs & Pharmacology Authors: Olivia Campagne, Donald E. Mager, Daniel Brazeau, Rocco C. Venuto, Kathleen M. Tornatore Tags: ORIGINAL ARTICLE Source Type: research

Pharmacokinetic ‐pharmacodynamic modelling of platelet response to ticagrelor in stable coronary artery disease and prior myocardial infarction patients
ConclusionsIn patients with stable CAD or a history of MI, near maximal platelet inhibition is achieved with both ticagrelor 60 and 90 mg twice daily. At modeled doses below 60mg, the response is overall reduced, more variable between patients, and patients will display greater peak ‐to‐trough variability. (Source: British Journal of Clinical Pharmacology)
Source: British Journal of Clinical Pharmacology - November 10, 2018 Category: Drugs & Pharmacology Authors: Magnus Åstrand, Carl Amilon, Daniel Röshammar, Anders Himmelmann, Dominick J. Angiolillo, Robert F. Storey, Paul A. Gurbel, Marc P. Bonaca, Bengt Hamrén Tags: ORIGINAL ARTICLE Source Type: research

Successful and safe long ‐term treatment of cerebral aspergillosis with high‐dose voriconazole guided by therapeutic drug monitoring
We report the case of a patient who had cerebral aspergillosis after otorhinolaryngologic surgery and who was successfully and safely treated with high ‐dose voriconazole (200 mg q6h) for more than 1 year thanks to a TDM‐guided approach coupled with pharmacological review and with genotyping of CYP2C19 polymorphisms. The findings support the idea that personalized medicine based on TDM coupled with the need of avoiding drug–drug interaction s may be helpful for maximizing the net benefit (probability of efficacyvs. probability of adverse events) of voriconazole in the management of long ‐term treatmen...
Source: British Journal of Clinical Pharmacology - November 9, 2018 Category: Drugs & Pharmacology Authors: Pier Giorgio Cojutti, Maria Merelli, Lorenzo Allegri, Giuseppe Damante, Matteo Bassetti, Federico Pea Tags: CASE REPORT Source Type: research

Increased risk of mycotic infections associated with sodium –glucose co‐transporter 2 inhibitors: a prescription sequence symmetry analysis
ConclusionInitiation of SGLT2i was associated with an increased risk for mycotic infections. Findings from this commercially insured population in the real world are consistent with evidence available from clinical trials. (Source: British Journal of Clinical Pharmacology)
Source: British Journal of Clinical Pharmacology - November 8, 2018 Category: Drugs & Pharmacology Authors: Sruthi Adimadhyam, Glen T. Schumock, Gregory S. Calip, Daphne E. Smith Marsh, Brian T. Layden, Todd A. Lee Tags: ORIGINAL ARTICLE Source Type: research

The journey of metformin from glycaemic control to mTOR inhibition and the suppression of tumour growth
Our knowledge of the effect of metformin on human health is increasing. In addition to its ability to improve the control of hyperglycaemia, metformin has been shown to reduce the burden o,f ageing via effects on damaged DNA and the process of apoptosis. Studies have shown that metformin may reduce the risk of cardiovascular disease through influences on body weight, blood pressure, cholesterol levels and the progression of atherosclerosis. Studies also suggest that metformin may be beneficial for neuro ‐psychiatric disorders, cognitive impairment and in reducing the risk of dementia, erectile dysfunction and Duchenne mu...
Source: British Journal of Clinical Pharmacology - November 8, 2018 Category: Drugs & Pharmacology Authors: Sam Amin, Andrew Lux, Finbar O'Callaghan Tags: REVIEW Source Type: research

Increased risk of mycotic infections associated with sodium –glucose co‐transporter 2 inhibitors: a prescription sequence symmetry analysis
ConclusionInitiation of SGLT2i was associated with an increased risk for mycotic infections. Findings from this commercially insured population in the real world are consistent with evidence available from clinical trials. (Source: British Journal of Clinical Pharmacology)
Source: British Journal of Clinical Pharmacology - November 8, 2018 Category: Drugs & Pharmacology Authors: Sruthi Adimadhyam, Glen T. Schumock, Gregory S. Calip, Daphne E. Smith Marsh, Brian T. Layden, Todd A. Lee Tags: ORIGINAL ARTICLE Source Type: research

The journey of metformin from glycaemic control to mTOR inhibition and the suppression of tumour growth
Our knowledge of the effect of metformin on human health is increasing. In addition to its ability to improve the control of hyperglycaemia, metformin has been shown to reduce the burden o,f ageing via effects on damaged DNA and the process of apoptosis. Studies have shown that metformin may reduce the risk of cardiovascular disease through influences on body weight, blood pressure, cholesterol levels and the progression of atherosclerosis. Studies also suggest that metformin may be beneficial for neuro ‐psychiatric disorders, cognitive impairment and in reducing the risk of dementia, erectile dysfunction and Duchenne mu...
Source: British Journal of Clinical Pharmacology - November 8, 2018 Category: Drugs & Pharmacology Authors: Sam Amin, Andrew Lux, Finbar O'Callaghan Tags: REVIEW Source Type: research